FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020559966> ?p ?o ?g. }

• W2020559966 endingPage "91" @default.
• W2020559966 startingPage "91" @default.
• W2020559966 abstract "Targeted therapies are nowadays a treatment option in metastatic non-small cell lung cancer, for which oncogenic drivers have been identified. The epidermal growth factor-receptor tyrosine kinase inhibitors gefitinib and erlotinib, are the standard of care for patients in whom tumors are presenting with an activating epidermal growth factor-receptor mutation, with new active agents like afatinib reaching clinics in the near future. Other genetic abnormalities have been documented in squamous and non-squamous lung cancer. The EML4-ALK gene fusion is a rare event, occurring in around 5% of lung cancer, quite exclusively in adenocarcinoma with a predominance of young non/light smokers. Detection of ALK-positive tumors is challenging, as there is no gold-standard technique. Fluorescence in situ hybridization is the method used in prospective trials assessing the activity of crizotinib and is recommended by the American FDA. Crizotinib is the first orally active inhibitor of receptor tyrosine kinases, including ALK and ROS1, in clinical practice. Impressive results came from a phase I study and are now confirmed in a large phase II study with response rate of 60%, whatever the number of previous lines of chemotherapy. Other ALK inhibitors are currently in the preclinical phase, and some are showing promising results in early phase I/II studies. This review aims to present the current knowledge on the EML4-ALK gene fusion, the pitfalls for the pathologist and the clinician in searching this abnormality, and to review the existing literature on ALK inhibitors under development, focusing their role compared to chemotherapy in non-small cell lung cancer patients." @default.
• W2020559966 created "2016-06-24" @default.
• W2020559966 creator A5002311944 @default.
• W2020559966 creator A5010064853 @default.
• W2020559966 creator A5010380574 @default.
• W2020559966 date "2012-12-01" @default.
• W2020559966 modified "2023-10-16" @default.
• W2020559966 title "Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer" @default.
• W2020559966 cites W1517005017 @default.
• W2020559966 cites W1997476230 @default.
• W2020559966 cites W2000397789 @default.
• W2020559966 cites W2004554806 @default.
• W2020559966 cites W2013653877 @default.
• W2020559966 cites W2015436643 @default.
• W2020559966 cites W2029218729 @default.
• W2020559966 cites W2031494655 @default.
• W2020559966 cites W2040636001 @default.
• W2020559966 cites W2044936103 @default.
• W2020559966 cites W2055402151 @default.
• W2020559966 cites W2066417528 @default.
• W2020559966 cites W2070525761 @default.
• W2020559966 cites W2074950286 @default.
• W2020559966 cites W2076315677 @default.
• W2020559966 cites W2077409585 @default.
• W2020559966 cites W2088720324 @default.
• W2020559966 cites W2092036762 @default.
• W2020559966 cites W2094903176 @default.
• W2020559966 cites W2096156234 @default.
• W2020559966 cites W2104830962 @default.
• W2020559966 cites W2104967681 @default.
• W2020559966 cites W2113327188 @default.
• W2020559966 cites W2118112346 @default.
• W2020559966 cites W2121425355 @default.
• W2020559966 cites W2123727052 @default.
• W2020559966 cites W2134787029 @default.
• W2020559966 cites W2135387401 @default.
• W2020559966 cites W2136950355 @default.
• W2020559966 cites W2139110945 @default.
• W2020559966 cites W2140333474 @default.
• W2020559966 cites W2142989887 @default.
• W2020559966 cites W2154905832 @default.
• W2020559966 cites W2161650275 @default.
• W2020559966 cites W2168106545 @default.
• W2020559966 cites W2168691181 @default.
• W2020559966 cites W2169836552 @default.
• W2020559966 cites W2170144893 @default.
• W2020559966 cites W2170874935 @default.
• W2020559966 cites W2626223149 @default.
• W2020559966 cites W1673567878 @default.
• W2020559966 doi "https://doi.org/10.2147/lctt.s12959" @default.
• W2020559966 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5312487" @default.
• W2020559966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28210128" @default.
• W2020559966 hasPublicationYear "2012" @default.
• W2020559966 type Work @default.
• W2020559966 sameAs 2020559966 @default.
• W2020559966 citedByCount "2" @default.
• W2020559966 countsByYear W20205599662014 @default.
• W2020559966 countsByYear W20205599662019 @default.
• W2020559966 crossrefType "journal-article" @default.
• W2020559966 hasAuthorship W2020559966A5002311944 @default.
• W2020559966 hasAuthorship W2020559966A5010064853 @default.
• W2020559966 hasAuthorship W2020559966A5010380574 @default.
• W2020559966 hasBestOaLocation W20205599661 @default.
• W2020559966 hasConcept C117643217 @default.
• W2020559966 hasConcept C121608353 @default.
• W2020559966 hasConcept C126322002 @default.
• W2020559966 hasConcept C143998085 @default.
• W2020559966 hasConcept C170493617 @default.
• W2020559966 hasConcept C2775999482 @default.
• W2020559966 hasConcept C2776232967 @default.
• W2020559966 hasConcept C2776256026 @default.
• W2020559966 hasConcept C2778087573 @default.
• W2020559966 hasConcept C2779422266 @default.
• W2020559966 hasConcept C2779438470 @default.
• W2020559966 hasConcept C2780580887 @default.
• W2020559966 hasConcept C2780586478 @default.
• W2020559966 hasConcept C2781064419 @default.
• W2020559966 hasConcept C2781182431 @default.
• W2020559966 hasConcept C2781230642 @default.
• W2020559966 hasConcept C42362537 @default.
• W2020559966 hasConcept C502942594 @default.
• W2020559966 hasConcept C71924100 @default.
• W2020559966 hasConceptScore W2020559966C117643217 @default.
• W2020559966 hasConceptScore W2020559966C121608353 @default.
• W2020559966 hasConceptScore W2020559966C126322002 @default.
• W2020559966 hasConceptScore W2020559966C143998085 @default.
• W2020559966 hasConceptScore W2020559966C170493617 @default.
• W2020559966 hasConceptScore W2020559966C2775999482 @default.
• W2020559966 hasConceptScore W2020559966C2776232967 @default.
• W2020559966 hasConceptScore W2020559966C2776256026 @default.
• W2020559966 hasConceptScore W2020559966C2778087573 @default.
• W2020559966 hasConceptScore W2020559966C2779422266 @default.
• W2020559966 hasConceptScore W2020559966C2779438470 @default.
• W2020559966 hasConceptScore W2020559966C2780580887 @default.
• W2020559966 hasConceptScore W2020559966C2780586478 @default.
• W2020559966 hasConceptScore W2020559966C2781064419 @default.
• W2020559966 hasConceptScore W2020559966C2781182431 @default.
• W2020559966 hasConceptScore W2020559966C2781230642 @default.

• next